Author

Alina S Gerrie

Assistant Professor, University of British Columbia - Cited by 1,850 - BC Cancer Agency - Leukemia/Bone Marrow Transplant Program of BC

Biography

Dr. Alina Gerrie joined the Leukemia/BMT Program of BC as an attending physician in January 2013.  She completed her medical training at the University of British Columbia and the University of Toronto. She then undertook a joint fellowship through the Royal College Clinical Investigator Program with both the Leukemia/BMT Program of BC and the Lymphoma Tumour Group at the BC Cancer Agency from 2010-2012
Title
Cited by
Year
Burkitt lymphoma international prognostic index
AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski, V Bachanova, ...Journal of clinical oncology 39 (10), 1129, 2021202
34
2021
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC
B Collinge, S Ben-Neriah, L Chong, M Boyle, A Jiang, T Miyata-Takata, ...Blood, The Journal of the American Society of Hematology 137 (16), 2196-2208, 2021202
29
2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
DA Bond, JM Switchenko, D Villa, K Maddocks, M Churnetski, AS Gerrie, ...Blood Advances 5 (23), 5179-59, 2021202
18
2021
Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
N Thomas, K Dreval, DS Gerhard, LK Hilton, JS Abramson, RF Ambinder, ...Blood, The Journal of the American Society of Hematology 141 (8), 904-9, 2023202
16
2023
Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population
W Alduaij, B Collinge, S Ben-Neriah, A Jiang, LK Hilton, M Boyle, ...Blood, The Journal of the American Society of Hematology 141 (20), 2493-2507, 2023202
8
2023
Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update
C Owen, V Banerji, N Johnson, A Gerrie, A Aw, C Chen, S RobinsonLeukemia Research, 10016, 2023202
7
2023
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
D Villa, E Hoster, O Hermine, W Klapper, M Szymczyk, A Bosly, ...Blood advances (18), 5285-5294, 2022202
6
2022
Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach
PTM Cheng, D Villa, RP Tonseth, DW Scott, AS Gerrie, CL Freeman, ...Blood Advances (18), 3647-36, 2021202
5
2021
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia
K Zhu, A Jamroz, S Huang, D Villa, CL Freeman, DW Scott, G Slack, ...British journal of haematology 198 (4), 684-692, 2022202
3
2022
Risk of central nervous system involvement in high-grade B-cell lymphoma with MYC and BCL2 rearrangements: analysis of a population-based cohort with routine fluorescence in …
Risk of central nervous system involvement in high-grade B-cell lymphoma with MYC and BCL rearrangements: analysis of a population-based cohort with routine fluorescence in …W Alduaij, A Jiang, D Villa, B Collinge, S Ben-Neriah, M Boyle, ...Blood 140 (Supplement 1), 133-1333, 0
2
2022
The clinical impact of COVID-19 on patients with cancer in British Columbia: An observational study
AS Mathews, A Paul, SY Irene, C McGahan, E Bhang, D Villa, K Gelmon, ...Heliyon 8 (1), 0
2
2022
Diffuse large B-cell lymphoma (DLBCL) patients with late relapses who are transplant-eligible have excellent outcomes and may represent unique biology
HS Ngu, LK Hilton, JA Rodrigo, D Villa, AS Gerrie, K Song, P Farinha, ...Blood 138, 499, 010
2
2021
Conservative management of presumed fetal anemia secondary to maternal chemotherapy for acute myeloid leukemia
CM Nowik, AS Gerrie, J WongAmerican Journal of Perinatology Reports 11 (04), e137-e141, 010
2
2021
whole genome sequencing of matched primary and relapsed DLBCL reveals distinct evolutionary dynamics associated with relapse timing
LK Hilton, B Collinge, CK Rushton, S Ben‐Neriah, K Dreval, BM Grande, ...Hematological Oncology 39, 010
2
2021
DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
N Thomas, K Dreval, DS Gerhard, LK Hilton, JS Abramson, NL Bartlett, ...Blood 40 (Supplement ), 734-736, 2022202
1
2022
Population-wide introduction of dose-adjusted EPOCH-R is associated with improved outcome of high grade B-cell lymphoma with MYC and BCL2 rearrangements with diffuse large B …
W Alduaij, LH Sehn, A Jiang, S Ben-Neriah, B Collinge, LK Hilton, ...Blood 38 (Supplement ), 458-458, 20220
1
2021
The Impact of Surveillance Imaging After Curative Intent Radiotherapy for Limited Stage Follicular Lymphoma
R Urban, R Chow, T Pickles, M Chan, J Livergant, A Gerrie, C Freeman, ...International Journal of Radiation Oncology, Biology, Physics (3), S05-S06, 20220
1
2021
Mortality from multiple myeloma within one year following autologous stem cell transplantation: defining an ultra-high risk population
HM Cherniawsky, H AlAhwal, Y Abou Mourad, D Forrest, A Gerrie, ...Clinical Lymphoma Myeloma and Leukemia 2 (7), 476-482, 20220
1
2021

Referred From: https://scholar.google.com/citations?user=iCTPAxcAAAAJ&hl=en

Cited by
Citations 1850
h-index 26
i10-index 54
Recommended Journals
Open Access Journals